What impact does maternal SSRI use have on neonatal platelet function?

The impact of maternal use of selective serotonin reuptake inhibitors (SSRIs) on neonatal platelet function is generally considered to result in no significant impact. Research indicates that, while SSRIs cross the placenta and can affect various aspects of fetal development and behavior, the specific influence on platelet function in newborns is not typically marked or clinically significant. This finding suggests that maternal SSRI use does not lead to altered platelet aggregation or function in neonates, making the choice of no impact the most accurate.

In contrast, increased or decreased function would imply a direct physiological effect on the newborn's platelet activity, which current studies do not support. Furthermore, stating that the impact only affects Caucasian newborns would imply a racial component that has not been established in this context, making this assertion weak if not unfounded.